Loading
Leukaemia specialist who built chemotherapy-light regimens combining inotuzumab, blinatumomab and ponatinib for adult ALL.
Elias Jabbour led the MD Anderson regimens combining low-intensity chemotherapy with inotuzumab ozogamicin and blinatumomab in older adults with ALL, and the chemotherapy-free ponatinib plus blinatumomab regimen for Philadelphia-positive ALL, which produce complete molecular remissions in most patients and challenge the need for transplant. He was senior author of INO-VATE and leads adult ALL research at MD Anderson.
Shares Blinatumomab, CD3, CD19, T-cell engagers (bispecific) and the tags all, immunotherapy.
Shares INO-VATE ALL, INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL, Blinatumomab, MD Anderson Cancer Center.
Shares Blinatumomab, CD19, T-cell engagers (bispecific), Acute lymphoblastic leukaemia and the tag all.
Shares Blinatumomab, CD3, CD19, T-cell engagers (bispecific).
Shares Blinatumomab, CD3, CD19, Acute lymphoblastic leukaemia.
Shares Blinatumomab, T-cell engagers (bispecific), Acute lymphoblastic leukaemia.
Shares CD3, CD19, T-cell engagers (bispecific).
Shares Blinatumomab, Acute lymphoblastic leukaemia and the tag all.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/